» Articles » PMID: 15846105

Met Activation and Receptor Dimerization in Cancer: a Role for the Sema Domain

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2005 Apr 23
PMID 15846105
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Ligand dependent activity of receptor tyrosine kinases is critical for modulating downstream signaling and cell proliferation. In normal cellular context, hepatocyte growth factor (HGF) regulates MET kinase activation and mediates cell proliferation, migration and motility. Recent elucidation of the MET extracellular domain suggests that the Sema domain, which bears structural similarity to other Semaphorins and Plexin family members, plays a critical role in ligand mediated receptor activation. Overexpression of MET which is observed in many cancers leads to ligand independent receptor dimerization and activation. Evidence to support a role for the Sema domain in cancer and therapeutic implications of targeting the Met Sema domain are discussed in this review.

Citing Articles

Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.

Raj S, Kesari K, Kumar A, Rathi B, Sharma A, Gupta P Mol Cancer. 2022; 21(1):31.

PMID: 35081970 PMC: 8790852. DOI: 10.1186/s12943-022-01503-1.


Fusion Genes Altered in Adult Malignant Gliomas.

You G, Fan X, Hu H, Jiang T, Chen C Front Neurol. 2021; 12:715206.

PMID: 34671307 PMC: 8520976. DOI: 10.3389/fneur.2021.715206.


High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation.

Huang R, Liu Y, Wang K, Wang Z, Zhang C, Zhang W CNS Neurosci Ther. 2021; 27(5):617-628.

PMID: 33645009 PMC: 8025647. DOI: 10.1111/cns.13627.


Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Bouattour M, Raymond E, Qin S, Cheng A, Stammberger U, Locatelli G Hepatology. 2017; 67(3):1132-1149.

PMID: 28862760 PMC: 5873445. DOI: 10.1002/hep.29496.


Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.

Zeng A, Yan W, Liu Y, Wang Z, Hu Q, Nie E Oncogene. 2017; 36(38):5369-5381.

PMID: 28504721 PMC: 5611480. DOI: 10.1038/onc.2017.134.